HC Wainwright Issues Pessimistic Forecast for EYPT Earnings

Key Points

• HC Wainwright slightly lowered its Q2 2026 EPS estimate for Eyepoint Pharmaceuticals to ($0.77) from ($0.76), while keeping a Buy rating and $30 price target on the stock.
• Eyepoint reported a Q1 loss of ($0.99) per share, wider than the expected ($0.79) loss, although revenue of $0.70 million beat estimates of $0.35 million.
• Analyst sentiment remains generally positive, with the stock carrying an average Buy rating and a consensus price target of $31.80, despite one Sell rating and continued losses.

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Equities research analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for shares of Eyepoint Pharmaceuticals in a report released on Thursday, May 7th. HC Wainwright analyst Y. Chen now anticipates that the company will earn ($0.77) per share for the quarter, down from their prior estimate of ($0.76). HC Wainwright has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Eyepoint Pharmaceuticals' current full-year earnings is ($3.18) per share. HC Wainwright also issued estimates for Eyepoint Pharmaceuticals' Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.45) EPS, FY2026 earnings at ($2.69) EPS and FY2027 earnings at ($1.74) EPS.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.20). The company had revenue of $0.70 million during the quarter, compared to analysts' expectations of $0.35 million. Eyepoint Pharmaceuticals had a negative return on equity of 108.31% and a negative net margin of 3,566.63%.

Several other analysts also recently commented on the company. Citigroup increased their price objective on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a "buy" rating in a research note on Monday, March 9th. Royal Bank Of Canada lowered their price objective on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an "outperform" rating for the company in a research note on Thursday. Chardan Capital upped their target price on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a "buy" rating in a report on Wednesday, March 4th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Eyepoint Pharmaceuticals currently has an average rating of "Buy" and an average price target of $31.80.

Eyepoint Pharmaceuticals Price Performance

Shares of Eyepoint Pharmaceuticals stock opened at $13.66 on Monday. The company has a market cap of $1.14 billion, a PE ratio of -3.90 and a beta of 1.76. Eyepoint Pharmaceuticals has a 52 week low of $5.30 and a 52 week high of $19.11. The business has a 50 day moving average price of $14.33 and a 200-day moving average price of $14.62.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. Cyndeo Wealth Partners LLC grew its holdings in Eyepoint Pharmaceuticals by 3.4% during the fourth quarter. Cyndeo Wealth Partners LLC now owns 22,990 shares of the company's stock valued at $420,000 after purchasing an additional 760 shares during the period. California State Teachers Retirement System grew its holdings in Eyepoint Pharmaceuticals by 20.6% during the fourth quarter. California State Teachers Retirement System now owns 4,654 shares of the company's stock valued at $85,000 after purchasing an additional 794 shares during the period. RWC Asset Management LLP grew its holdings in Eyepoint Pharmaceuticals by 6.4% during the fourth quarter. RWC Asset Management LLP now owns 17,235 shares of the company's stock valued at $315,000 after purchasing an additional 1,040 shares during the period. MCF Advisors LLC grew its holdings in Eyepoint Pharmaceuticals by 8.3% during the fourth quarter. MCF Advisors LLC now owns 14,921 shares of the company's stock valued at $273,000 after purchasing an additional 1,149 shares during the period. Finally, Raymond James Financial Inc. grew its holdings in Eyepoint Pharmaceuticals by 11.0% during the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company's stock valued at $112,000 after purchasing an additional 1,177 shares during the period. 99.41% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of the stock in a transaction on Friday, April 17th. The stock was sold at an average price of $15.00, for a total transaction of $36,555.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.46% of the company's stock.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.